Mark Bamforth founded Brammer Bio, a best-in-class viral vector contract and development manufacturing organization (CDMO) supporting cell and gene therapy innovators.
Brammer’s team has grown rapidly from 110 in 2016 to over 400 today. Brammer is based in Alachua, FL, for early stage development and clinical manufacturing, and in Cambridge, MA, for late clinical and commercial manufacturing of five viral vector platforms. Brammer is also building additional gene therapy commercial capacity in Lexington, MA, which will be on-line by mid-2019.
In 2010, Bamforth founded a biologics CDMO, Gallus BioPharmaceuticals, acquiring a world-class facility and team in St. Louis, MO, and a commercial supply agreement with Janssen. Gallus tripled through organic growth and merging with Laureate Biopharma. Gallus was sold to DPx Holdings B.V. in 2014.
Bamforth previously had 22 years of experience in the UK and USA running a diverse, global manufacturing operation and a pharmaceutical CMO business for Genzyme and served as a corporate officer for 9 years. He began his career as a petroleum engineer exploring for North Sea oil with Britoil, then as a chemical engineer in the whisky industry with Whitbread.
Bamforth serves on the board of Avid Bioservices, a public CDMO company, MassBio Board, Wentworth Institute of Technology board, Entrepreneurial Scotland’s board and is a founding-trustee of the Saltire Programs. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.